Become a Member

Topic Archives: Exelixis (EXEL)

  • Navellier’s “Five Times Your Money in a Stock That Stops Cancer”

    What's being teased by Navellier's Emerging Growth?

    28 Comments Read More
  • Sells: Clearing out small positions to build cash

    Or perhaps a better title would have been, “Pruning during a forest fire.” As the markets go through wild swings (no, that’s not right — swings move both ways — I mean “wild drops”), I feel as I often do at times like these: That I wish I had more cash to invest. I’d never […]

    4 Comments Read More
  • Swath of Personal Selling — not a market call

    This note should not be considered to indicate my opinions on any of the stocks herein, or to be any kind of market prognostication about the months ahead (I’m personally worried about the market this fall, but I rarely trade on such short term worries). But since I’ve promised to disclose my portfolio to you, […]

    4 Comments Read More
  • A Tale of Two Fund-raisings

    If you happen to follow any of the stocks I own, you might have noticed two big movers lately, in opposite directions — Exelixis moving up, and ABB Grain moving down. In my opinion, neither one has huge implications, but both of these moves are because the company is raising money for future projects.  In […]

    Leave a comment Read More
  • Comments

  • $PTLA Names Scott Garland President and CEO effective October 8. Formerly Relypsa president and $EXEL CCO https://twitt...

  • An excellent exegesis of excecrable Navellierian exaggeration. I also owned it way back then, and after losing some mone...

  • $MOTELY Fool's top 4 BIO Pics for 2018.Just got a teaser ad for the MF Explorer investment newsletter. They are nomin...

  • I bought $EXEL a few years ago for $11 and change left it alone unil they had a viable product, just sold it when it hit...

  • Some of the companies at the Cantor Fitzgerald Conference this week. Many are also presenting at the Landenburg Thalmann...

  • $ AFMD longFrom Briefing.comExelixis (EXEL) initiated with Buy and $33 tgt, Affimed Therapeutics (AFMD) with Buy...

  • $EXEL Doc, thanks for your summation. If you expect failure in the HCC trial that's reason enough for me not to pull th...

  • I'll have a crack at it. It's hard to justify covering, and logging research hours poking into, companies where we see n...

  • $EXEL,$BMY Exelixis and Bristol-Myers are two companies that have gotten relatively scant attention here over the years...

  • $AUPH: My hometown is Melbourne, maybe I should go on a reconnaissance mission as an attaché-for the Gummune. Do you ne...

  • Ophad Hammer blog on $ESPR, $TRVN,$EXEL, $ARGL. Very long ESPR, long EXELhttp://www.orf-blog.com/biotech-portfolio-u...

  • $EXEL #RCC$EXEL and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Thera...

  • Below is an interesting blog article - another affirmation and salutation to Dr. KSS's biotech vision:"2016 Biotech ...

  • Exelixis (EXEL) Cabozantinib bests Sunitinib for mRCC (kidney cancers) .http://www.onclive.com/conference-coverage/e...

  • Exelixis, Ipsen Say European Commission Approves Kidney Cancer Drug 8:17 am ET (Dow Jones)...

  • $EXELDon't want to steal your time - but do you have a quick opinion about exelixis and its recent mighty run? Haven...

  • $EXEL - From SA: http://seekingalpha.com/news/3187291-exelixis-cabometyx-superior-novartis-afinitor-extending-survival-k...

  • Thank you for the information. I do not own any $EXEL now, but did, and was wondering if would be a good repurchase. I...

  • Someone was asking about Exelixis in the context of its pursuing approval for cabozantinib for renal cell cancer. Keep i...

  • This data will probably move Exelixis (EXEL) Monday morning. http://www.nejm.org/doi/full/10.1056/NEJMoa1408758?af%3DR%...

  • I am a mite concerned here for Exelixis longs. Let's keep in mind: the phase 3 cabozantinib trial has not yet finished. ...

  • $EXELMy questions are How much would Cabozantinib add to the bottom line per share given that Novartis is in this ...

  • Feuerstein thoughts on Exelixis and Puma Bio upcoming catalysts. http://www.thestreet.com/story/13199783/1/biotech-stoc...

  • Mr Hall: I am not a drive-by coin-op when-the-urge-hits-you looker up of information on stocks for people. The etiquette...

  • Hi Dr. KSS, just wanted to know if you had an opinion on EXEL? ASCO Reaffirms Why I'm Holding Exelixis By Investope...

  • Need some help on these tickers, they look interesting to me or other readers. Please volunteer if you are able to pick...

  • XBI HOLDINGS volume order Symbol Description Percent of Net Assets DYAX Dyax Corp 1.75% ESPR Esperion Therapeuti...

  • Expect heavy selling pressure on small cap bio in wake of today's $EXEL brouhaha. $EXEL will be down 50 per cent. Probab...

  • Whilst perusing my portfolio to find a share to dump in order to put in a (limit) order for these new recommendations, I...

  • Exelixis also has a phase III trial for a prostate cancer drug, cabozantinib, which they expected to be stopped because ...

  • As requested, I looked at Exelixis. This company is to me like being in an air traffic control tower; the wind is changi...

  • EXELIXIS announces prelim results in trial of Cobimetinib partnered with Roche.- Data from BRIM7, ongoing phas...

  • KennyG, Thanks for the link. That helps explain some of the drop. I wonder how Cabo would have measured up against str...

  • Exelixis, Inc. (EXEL) announced that the Independent Data Monitoring Committee (IDMC) notified the company today that a ...

  • Interim results on Exelixis' Comet trial for CRPC (castration resistant prostate cancer)http://finance.yahoo.com/new...

  • Thanks to all the outstanding contributors to this continually amazing site! I've been overwhelmed by the breadth and de...

  • Extraordinary really that Dr. KSS is willing to share his vast knowledge with us all. I've become an avid reader of this...

  • Wondering as well what Dr. K and others may think of Exelixis. EXEL's primary compound, Cometriq (Cabozantinib), has bee...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info